33 results on '"Olmos, Ismael"'
Search Results
2. Clozapine safety monitoring and related research in psychiatry and neurology in South America: A scoping review
- Author
-
Baptista, Trino, Serrano, Ana, Presti, Alirio Perez Lo, Fernandez-Arana, Alberto, Elkis, Helio, Motuca, Mariano, Olmos, Ismael, and Schoretsanitis, Georgios
- Published
- 2024
- Full Text
- View/download PDF
3. Exploring low clozapine C/D ratios, inverted clozapine-norclozapine ratios and undetectable concentrations as measures of non-adherence in clozapine patients: A literature review and a case series of 17 patients from 3 studies
- Author
-
Ruan, Can-Jun, Olmos, Ismael, Ricciardi, Carina, Schoretsanitis, Georgios, Vincent, Philippe D., Anıl Yağcıoğlu, A. Elif, Eap, Chin B., Baptista, Trino, Clark, Scott R., Fernandez-Egea, Emilio, Kim, Se Hyun, Lane, Hsien-Yuan, Leung, Jonathan, Maroñas Amigo, Olalla, Motuca, Mariano, Every-Palmer, Susanna, Procyshyn, Ric M., Rohde, Christopher, Suhas, Satish, Schulte, Peter F.J., Spina, Edoardo, Takeuchi, Hiroyoshi, Verdoux, Hélène, Correll, Christoph U., Molden, Espen, De Las Cuevas, Carlos, and de Leon, Jose
- Published
- 2024
- Full Text
- View/download PDF
4. Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition
- Author
-
Schoretsanitis, Georgios, Anıl Yağcıoğlu, A. Elif, Ruan, Can-Jun, Eap, Chin B., Molden, Espen, Baptista, Trino, Clark, Scott R., Fernandez-Egea, Emilio, Kim, Se Hyun, Lane, Hsien-Yuan, Leung, Jonathan, Maroñas Amigo, Olalla, Motuca, Mariano, Olmos, Ismael, Every-Palmer, Susanna, Procyshyn, Ric M., Rohde, Christopher, Satish, Suhas, Schulte, Peter F.J., Spina, Edoardo, Takeuchi, Hiroyoshi, Verdoux, Hélène, Correll, Christoph U., and de Leon, Jose
- Published
- 2024
- Full Text
- View/download PDF
5. Guía internacional para una dosificación más segura de la clozapina en adultos mediante el uso de 6 titulaciones personalizadas de dosis basados en la etnicidad, la proteína C reactiva y los niveles de clozapina
- Author
-
de Leon, Jose, Schoretsanitis, Georgios, Smith, Robert L., Molden, Espen, Solismaa, Anssi, Seppälä, Niko, Kopeček, Miloslav, Švancer, Patrik, Olmos, Ismael, Ricciardi, Carina, Iglesias-Garcia, Celso, Iglesias-Alonso, Ana, Spina, Edoardo, Ruan, Can-Jun, Wang, Chuan-Yue, Wang, Gang, Tang, Yi-Lang, Lin, Shih-Ku, Lane, Hsien-Yuan, Kim, Yong Sik, Kim, Se Hyun, Rajkumar, Anto P., González-Esquivel, Dinora F., Jung-Cook, Helgi, Baptista, Trino, Rohde, Christopher, Nielsen, Jimmi, Verdoux, Hélène, Quiles, Clelia, Sanz, Emilio J., De las Cuevas, Carlos, Cohen, Dan, Schulte, Peter F.J., Ertuğrul, Aygün, Anıl Yağcıoğlu, A. Elif, Chopra, Nitin, McCollum, Betsy, Shelton, Charles, Cotes, Robert O., Kaithi, Arun R., Kane, John M., Farooq, Saeed, Ng, Chee H., Bilbily, John, Hiemke, Christoph, López-Jaramillo, Carlos, McGrane, Ian, Lana, Fernando, Eap, Chin B., Arrojo-Romero, Manuel, Rădulescu, Flavian Ştefan, Seifritz, Erich, Every-Palmer, Susanna, Bousman, Chad A., Bebawi, Emmanuel, Bhattacharya, Rahul, Kelly, Deanna L., Otsuka, Yuji, Lazary, Judit, Torres, Rafael, Yecora, Agustin, Motuca, Mariano, Chan, Sherry Kit Wa, Zolezzi, Monica, Ouanes, Sami, De Berardis, Domenico, Grover, Sandeep, Procyshyn, Ric M., Adebayo, Richard A., Kirilochev, Oleg O., Soloviev, Andrey, Fountoulakis, Konstantinos N., Wilkowska, Alina, Cubała, Wiesław Jerzy, Ayub, Muhammad, Silva, Alzira, Bonelli, Raphael M., Villagrán-Moreno, José María, Crespo-Facorro, Benedicto, Temmingh, Henk, Decloedt, Eric, Pedro, Maria Rosel, Takeuchi, Hiroyoshi, Tsukahara, Masaru, Gründer, Gerhard, Sagud, Marina, Celofiga, Andreja, Ignjatovic Ristic, Dragana, Ortiz, Bruno Bertolucci, Elkis, Helio, Pacheco Palha, António José, Llerena, Adrián, Fernandez-Egea, Emilio, Siskind, Dan, Weizman, Abraham, Masmoudi, Rim, Mohd Saffian, Shamin, Leung, Jonathan G., Buckley, Peter F., Marder, Stephen R., Citrome, Leslie, Freudenreich, Oliver, Correll, Christoph U., and Müller, Daniel J.
- Published
- 2023
- Full Text
- View/download PDF
6. Clozapine safety monitoring and related research in psychiatry and neurology in South America: A scoping review
- Author
-
Baptista, Trino, primary, Serrano, Ana, additional, Presti, Alirio Perez Lo, additional, Fernandez-Arana, Alberto, additional, Elkis, Helio, additional, Motuca, Mariano, additional, Olmos, Ismael, additional, and Schoretsanitis, Georgios, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Clozapine ultrarapid metabolism during weak induction probably exists but requires careful diagnosis. A literature review, five new cases and a proposed definition
- Author
-
Schoretsanitis, Georgios, primary, Anıl Yağcıoğlu, A. Elif, additional, Ruan, Can-Jun, additional, Eap, Chin B., additional, Molden, Espen, additional, Baptista, Trino, additional, Clark, Scott R., additional, Fernandez-Egea, Emilio, additional, Kim, Se Hyun, additional, Lane, Hsien-Yuan, additional, Leung, Jonathan, additional, Maroñas Amigo, Olalla, additional, Motuca, Mariano, additional, Olmos, Ismael, additional, Every-Palmer, Susanna, additional, Procyshyn, Ric M., additional, Rohde, Christopher, additional, Satish, Suhas, additional, Schulte, Peter F.J., additional, Spina, Edoardo, additional, Takeuchi, Hiroyoshi, additional, Verdoux, Hélène, additional, Correll, Christoph U., additional, and de Leon, Jose, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Escaping the Long Shadow Cast by Agranulocytosis:Reflections on Clozapine Pharmacovigilance Focused on the United Kingdom
- Author
-
de Leon, Jose, Arrojo-Romero, Manuel, Verdoux, Hélène, Ruan, Can-Jun, Schoretsanitis, Georgios, Rohde, Christopher, Cohen, Dan, Schulte, Peter F.J., Kim, Se Hyun, Cotes, Robert O., Leung, Jonathan G., Otsuka, Yuji, Kirilochev, Oleg O., Baptista, Trino, Grover, Sandeep, Every-Palmer, Susanna, Clark, Scott R., McGrane, Ian R., Motuca, Mariano, Olmos, Ismael, Wilkowska, Alina, Sagud, Marina, Anil Yağcioğlu, A. Elif, Ristic, Dragana Ignjatovic, Lazary, Judit, Sanz, Emilio J., and De Las Cuevas, Carlos
- Subjects
clozapine/adverse effects, clozapine/administration and dosage, clozapine/metabolism, clozapine/therapeutic use, clozapine/toxicity, COVID-19, drug labeling, infection, inflammation, mortality/drug effects, pneumonia, schizophrenia, sex, smoking ,drug labeling ,mortality/drug effects ,clozapine/therapeutic use ,COVID-19 ,clozapine/toxicity ,infection ,smoking ,clozapine/administration and dosage ,schizophrenia ,Psychiatry and Mental health ,clozapine/metabolism ,inflammation ,clozapine/adverse effects ,pneumonia ,sex ,Pharmacology (medical) - Abstract
Purpose/Background A recent article in this journal presented a US perspective regarding the modernization of clozapine prescription and proposed an escape from the long shadow cast by agranulocytosis. Methods Here, an international group of collaborators discusses a point of view complementary to the US view by focusing on worldwide outcomes of clozapine usage that may be uneven in terms of frequency of clozapine adverse drug reactions. Findings/Results Studies from the Scandinavian national registries (Finland and Denmark) did not find increased mortality in clozapine patients or any clear evidence of the alleged toxicity of clozapine. Data on clozapine-associated fatal outcomes were obtained from 2 recently published pharmacovigilance studies and from the UK pharmacovigilance database. A pharmacovigilance study focused on physician reports to assess worldwide lethality of drugs from 2010 to 2019 found 968 clozapine-associated fatal outcomes in the United Kingdom. Moreover, the United Kingdom accounted for 55% (968 of 1761) of worldwide and 90% (968 of 1073) of European fatal clozapine-associated outcomes. In a pharmacovigilance study from the UK database (from 2008 to 2017), clozapine was associated with 383 fatal outcomes/year including all reports from physicians and nonphysicians. From 2018 to 2021, UK clozapine-associated fatal outcomes increased to 440/year. Implications/Conclusions The interpretation of fatal outcomes in each country using pharmacovigilance databases is limited and only allows gross comparisons; even with those limitations, the UK data seem concerning. Pneumonia and myocarditis may be more important than agranulocytosis in explaining the uneven distribution of fatal outcomes in clozapine patients across countries.
- Published
- 2023
9. Escaping the Long Shadow Cast by Agranulocytosis
- Author
-
de Leon, Jose, primary, Arrojo-Romero, Manuel, additional, Verdoux, Hélène, additional, Ruan, Can-Jun, additional, Schoretsanitis, Georgios, additional, Rohde, Christopher, additional, Cohen, Dan, additional, Schulte, Peter F.J., additional, Kim, Se Hyun, additional, Cotes, Robert O., additional, Leung, Jonathan G., additional, Otsuka, Yuji, additional, Kirilochev, Oleg O., additional, Baptista, Trino, additional, Grover, Sandeep, additional, Every-Palmer, Susanna, additional, Clark, Scott R., additional, McGrane, Ian R., additional, Motuca, Mariano, additional, Olmos, Ismael, additional, Wilkowska, Alina, additional, Sagud, Marina, additional, Anıl Yağcıoğlu, A. Elif, additional, Ristic, Dragana Ignjatovic, additional, Lazary, Judit, additional, Sanz, Emilio J., additional, and De Las Cuevas, Carlos, additional
- Published
- 2023
- Full Text
- View/download PDF
10. Esquizofrenia resistente al tratamiento I Concepto e impacto clínico
- Author
-
Toledo, Mauricio, primary, Olmos, Ismael, additional, and Ricciardi, Carina, additional
- Published
- 2022
- Full Text
- View/download PDF
11. La confianza en los tratamientos
- Author
-
Olmos, Ismael, primary
- Published
- 2022
- Full Text
- View/download PDF
12. Data sources for drug utilization research in Latin American countries-A cross-national study: DASDUR-LATAM study
- Author
-
Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Lopes, Luciane C, Salas, Maribel, Osorio-de-Castro, Claudia Garcia Serpa, Leal, Lisiane Freitas, Doubova, Svetlana V, Cañás, Martín, Dreser, Anahi, Acosta, Angela, Baldoni, Andre Oliveira, de Cássia Bergamaschi, Cristiane, Mota, Daniel Marques, Gómez-Galicia, Diana L, Sepúlveda-Viveros, Dino, Delgado, Edgard Narvaez, da Costa Lima, Elisangela, Chandia, Felipe Vera, Ferre, Felipe, Marin, Gustavo H, Olmos, Ismael, Zimmermann, Ivan R, Fulone, Izabela, Roldán-Saelzer, Juan, Sánchez-Salgado, Juan Carlos, Castro-Pastrana, Lucila I, de Souza, Luiz Jupiter Carneiro, Beltrán, Manuel Machado, Silva, Marcus Tolentino, Mena, María Belén, de França Fonteles, Marta Maria, Urtasun, Martín A, Tarapués, Mónica, Hernández, Patricia Granja, Medero, Natalia, Herrera-Comoglio, Raquel, Barberato-Filho, Silvio, Galvão, Taís Freire, Luiza, Vera Lucia, Santa-Ana-Tellez, Yared, Rodríguez-Tanta, Yesenia, Elseviers, Monique, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Lopes, Luciane C, Salas, Maribel, Osorio-de-Castro, Claudia Garcia Serpa, Leal, Lisiane Freitas, Doubova, Svetlana V, Cañás, Martín, Dreser, Anahi, Acosta, Angela, Baldoni, Andre Oliveira, de Cássia Bergamaschi, Cristiane, Mota, Daniel Marques, Gómez-Galicia, Diana L, Sepúlveda-Viveros, Dino, Delgado, Edgard Narvaez, da Costa Lima, Elisangela, Chandia, Felipe Vera, Ferre, Felipe, Marin, Gustavo H, Olmos, Ismael, Zimmermann, Ivan R, Fulone, Izabela, Roldán-Saelzer, Juan, Sánchez-Salgado, Juan Carlos, Castro-Pastrana, Lucila I, de Souza, Luiz Jupiter Carneiro, Beltrán, Manuel Machado, Silva, Marcus Tolentino, Mena, María Belén, de França Fonteles, Marta Maria, Urtasun, Martín A, Tarapués, Mónica, Hernández, Patricia Granja, Medero, Natalia, Herrera-Comoglio, Raquel, Barberato-Filho, Silvio, Galvão, Taís Freire, Luiza, Vera Lucia, Santa-Ana-Tellez, Yared, Rodríguez-Tanta, Yesenia, and Elseviers, Monique
- Published
- 2022
13. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
- Author
-
de Leon, Jose, Schoretsanitis, Georgios, Smith, Robert L., Molden, Espen, Solismaa, Anssi, Seppala, Niko, Kopecek, Miloslav, Svancer, Patrik, Olmos, Ismael, Ricciardi, Carina, Iglesias-Garcia, Celso, Iglesias-Alonso, Ana, Spina, Edoardo, Ruan, Can-Jun, Wang, Chuan-Yue, Wang, Gang, Tang, Yi-Lang, Lin, Shih-Ku, Lane, Hsien-Yuan, Kim, Yong Sik, Kim, Se Hyun, Rajkumar, Anto P., Gonzalez-Esquivel, Dinora F., Jung-Cook, Helgi, Baptista, Trino, Rohde, Christopher, Nielsen, Jimmi, Verdoux, Helene, Quiles, Clelia, Sanz, Emilio J., De las Cuevas, Carlos, Cohen, Dan, Schulte, Peter F. J., Ertugrul, Aygun, Chopra, Nitin, McCollum, Betsy, Shelton, Charles, Cotes, Robert O., Kaithi, Arun R., Kane, John M., Farooq, Saeed, Ng, Chee H., Bilbily, John, Hiemke, Christoph, Lopez-Jaramillo, Carlos, McGrane, Ian, Lana, Fernando, Eap, Chin B., Arrojo-Romero, Manuel, Seifritz, Erich, Every-Palmer, Susanna, Bousman, Chad A., Bebawi, Emmanuel, Bhattacharya, Rahul, Kelly, Deanna L., Otsuka, Yuji, Lazary, Judit, Torres, Rafael, Yecora, Agustin, Motuca, Mariano, Chan, Sherry K. W., Zolezzi, Monica, Ouanes, Sami, De Berardis, Domenico, Grover, Sandeep, Procyshyn, Ric M., Adebayo, Richard A., Kirilochev, Oleg O., Soloviev, Andrey, Fountoulakis, Konstantinos N., Wilkowska, Alina, Ayub, Muhammad, Silva, Alzira, Bonelli, Raphael M., Villagran-Moreno, Jose M., Crespo-Facorro, Benedicto, Temmingh, Henk, Decloedt, Eric, Pedro, Maria R., Takeuchi, Hiroyoshi, Tsukahara, Masaru, Gruender, Gerhard, Sagud, Marina, Celofiga, Andreja, Ristic, Dragana Ignjatovic, Ortiz, Bruno B., Elkis, Helio, Palha, Antonio J. Pacheco, LLerena, Adrian, Fernandez-Egea, Emilio, Siskind, Dan, Weizman, Abraham, Masmoudi, Rim, Saffian, Shamin Mohd, Leung, Jonathan G., Buckley, Peter F., Marder, Stephen R., Citrome, Leslie, Freudenreich, Oliver, Correll, Christoph U., Muller, Daniel J., Anil Yagcioglu, A. Elif, Radulescu, Flavian S., Cubala, Wieslaw J., de Leon, Jose, Schoretsanitis, Georgios, Smith, Robert L., Molden, Espen, Solismaa, Anssi, Seppala, Niko, Kopecek, Miloslav, Svancer, Patrik, Olmos, Ismael, Ricciardi, Carina, Iglesias-Garcia, Celso, Iglesias-Alonso, Ana, Spina, Edoardo, Ruan, Can-Jun, Wang, Chuan-Yue, Wang, Gang, Tang, Yi-Lang, Lin, Shih-Ku, Lane, Hsien-Yuan, Kim, Yong Sik, Kim, Se Hyun, Rajkumar, Anto P., Gonzalez-Esquivel, Dinora F., Jung-Cook, Helgi, Baptista, Trino, Rohde, Christopher, Nielsen, Jimmi, Verdoux, Helene, Quiles, Clelia, Sanz, Emilio J., De las Cuevas, Carlos, Cohen, Dan, Schulte, Peter F. J., Ertugrul, Aygun, Chopra, Nitin, McCollum, Betsy, Shelton, Charles, Cotes, Robert O., Kaithi, Arun R., Kane, John M., Farooq, Saeed, Ng, Chee H., Bilbily, John, Hiemke, Christoph, Lopez-Jaramillo, Carlos, McGrane, Ian, Lana, Fernando, Eap, Chin B., Arrojo-Romero, Manuel, Seifritz, Erich, Every-Palmer, Susanna, Bousman, Chad A., Bebawi, Emmanuel, Bhattacharya, Rahul, Kelly, Deanna L., Otsuka, Yuji, Lazary, Judit, Torres, Rafael, Yecora, Agustin, Motuca, Mariano, Chan, Sherry K. W., Zolezzi, Monica, Ouanes, Sami, De Berardis, Domenico, Grover, Sandeep, Procyshyn, Ric M., Adebayo, Richard A., Kirilochev, Oleg O., Soloviev, Andrey, Fountoulakis, Konstantinos N., Wilkowska, Alina, Ayub, Muhammad, Silva, Alzira, Bonelli, Raphael M., Villagran-Moreno, Jose M., Crespo-Facorro, Benedicto, Temmingh, Henk, Decloedt, Eric, Pedro, Maria R., Takeuchi, Hiroyoshi, Tsukahara, Masaru, Gruender, Gerhard, Sagud, Marina, Celofiga, Andreja, Ristic, Dragana Ignjatovic, Ortiz, Bruno B., Elkis, Helio, Palha, Antonio J. Pacheco, LLerena, Adrian, Fernandez-Egea, Emilio, Siskind, Dan, Weizman, Abraham, Masmoudi, Rim, Saffian, Shamin Mohd, Leung, Jonathan G., Buckley, Peter F., Marder, Stephen R., Citrome, Leslie, Freudenreich, Oliver, Correll, Christoph U., Muller, Daniel J., Anil Yagcioglu, A. Elif, Radulescu, Flavian S., and Cubala, Wieslaw J.
- Abstract
This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas' original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300-600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75-150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175-300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100-200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250-400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150-300 mg/day, and 6) in the US with ancestries other than from Asia or the original people fr
- Published
- 2022
14. Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
- Author
-
de Leon, Jose, additional, Schoretsanitis, Georgios, additional, Smith, Robert L., additional, Molden, Espen, additional, Solismaa, Anssi, additional, Seppälä, Niko, additional, Kopeček, Miloslav, additional, Švancer, Patrik, additional, Olmos, Ismael, additional, Ricciardi, Carina, additional, Iglesias-Garcia, Celso, additional, Iglesias-Alonso, Ana, additional, Spina, Edoardo, additional, Ruan, Can-Jun, additional, Wang, Chuan-Yue, additional, Wang, Gang, additional, Tang, Yi-Lang, additional, Lin, Shih-Ku, additional, Lane, Hsien-Yuan, additional, Kim, Yong Sik, additional, Kim, Se Hyun, additional, Rajkumar, Anto P., additional, González-Esquivel, Dinora F., additional, Jung-Cook, Helgi, additional, Baptista, Trino, additional, Rohde, Christopher, additional, Nielsen, Jimmi, additional, Verdoux, Hélène, additional, Quiles, Clelia, additional, Sanz, Emilio J., additional, De Las Cuevas, Carlos, additional, Cohen, Dan, additional, Schulte, Peter F.J., additional, Ertuğrul, Aygün, additional, Anıl Yağcıoğlu, A. Elif, additional, Chopra, Nitin, additional, McCollum, Betsy, additional, Shelton, Charles, additional, Cotes, Robert O., additional, Kaithi, Arun R., additional, Kane, John M., additional, Farooq, Saeed, additional, Ng, Chee H., additional, Bilbily, John, additional, Hiemke, Christoph, additional, López-Jaramillo, Carlos, additional, McGrane, Ian, additional, Lana, Fernando, additional, Eap, Chin B., additional, Arrojo-Romero, Manuel, additional, Rădulescu, Flavian Ş., additional, Seifritz, Erich, additional, Every-Palmer, Susanna, additional, Bousman, Chad A., additional, Bebawi, Emmanuel, additional, Bhattacharya, Rahul, additional, Kelly, Deanna L., additional, Otsuka, Yuji, additional, Lazary, Judit, additional, Torres, Rafael, additional, Yecora, Agustin, additional, Motuca, Mariano, additional, Chan, Sherry K.W., additional, Zolezzi, Monica, additional, Ouanes, Sami, additional, De Berardis, Domenico, additional, Grover, Sandeep, additional, Procyshyn, Ric M., additional, Adebayo, Richard A., additional, Kirilochev, Oleg O., additional, Soloviev, Andrey, additional, Fountoulakis, Konstantinos N., additional, Wilkowska, Alina, additional, Cubała, Wiesław J., additional, Ayub, Muhammad, additional, Silva, Alzira, additional, Bonelli, Raphael M., additional, Villagrán-Moreno, José M., additional, Crespo-Facorro, Benedicto, additional, Temmingh, Henk, additional, Decloedt, Eric, additional, Pedro, Maria R., additional, Takeuchi, Hiroyoshi, additional, Tsukahara, Masaru, additional, Gründer, Gerhard, additional, Sagud, Marina, additional, Celofiga, Andreja, additional, Ignjatovic Ristic, Dragana, additional, Ortiz, Bruno B., additional, Elkis, Helio, additional, Pacheco Palha, António J., additional, LLerena, Adrián, additional, Fernandez-Egea, Emilio, additional, Siskind, Dan, additional, Weizman, Abraham, additional, Masmoudi, Rim, additional, Mohd Saffian, Shamin, additional, Leung, Jonathan G., additional, Buckley, Peter F., additional, Marder, Stephen R., additional, Citrome, Leslie, additional, Freudenreich, Oliver, additional, Correll, Christoph U., additional, and Müller, Daniel J., additional
- Published
- 2022
- Full Text
- View/download PDF
15. Data sources for drug utilization research in Latin American countries—A cross‐national study: DASDUR‐LATAM study
- Author
-
Lopes, Luciane C., primary, Salas, Maribel, additional, Osorio‐de‐Castro, Claudia Garcia Serpa, additional, Leal, Lisiane Freitas, additional, Doubova, Svetlana V., additional, Cañás, Martín, additional, Dreser, Anahi, additional, Acosta, Angela, additional, Baldoni, Andre Oliveira, additional, de Cássia Bergamaschi, Cristiane, additional, Mota, Daniel Marques, additional, Gómez‐Galicia, Diana L., additional, Sepúlveda‐Viveros, Dino, additional, Delgado, Edgard Narvaez, additional, da Costa Lima, Elisangela, additional, Chandia, Felipe Vera, additional, Ferre, Felipe, additional, Marin, Gustavo H., additional, Olmos, Ismael, additional, Zimmermann, Ivan R., additional, Fulone, Izabela, additional, Roldán‐Saelzer, Juan, additional, Sánchez‐Salgado, Juan Carlos, additional, Castro‐Pastrana, Lucila I., additional, de Souza, Luiz Jupiter Carneiro, additional, Beltrán, Manuel Machado, additional, Silva, Marcus Tolentino, additional, Mena, María Belén, additional, de França Fonteles, Marta Maria, additional, Urtasun, Martín A., additional, Tarapués, Mónica, additional, Hernández, Patricia Granja, additional, Medero, Natalia, additional, Herrera‐Comoglio, Raquel, additional, Barberato‐Filho, Silvio, additional, Galvão, Taís Freire, additional, Luiza, Vera Lucia, additional, Santa‐Ana‐Tellez, Yared, additional, Rodríguez ‐ Tanta, Yesenia, additional, and Elseviers, Monique, additional
- Published
- 2022
- Full Text
- View/download PDF
16. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
- Author
-
de Leon, Jose, additional, Schoretsanitis, Georgios, additional, Smith, Robert L., additional, Molden, Espen, additional, Solismaa, Anssi, additional, Seppälä, Niko, additional, Kopeček, Miloslav, additional, Švancer, Patrik, additional, Olmos, Ismael, additional, Ricciardi, Carina, additional, Iglesias-Garcia, Celso, additional, Iglesias-Alonso, Ana, additional, Spina, Edoardo, additional, Ruan, Can-Jun, additional, Wang, Chuan-Yue, additional, Wang, Gang, additional, Tang, Yi-Lang, additional, Lin, Shih-Ku, additional, Lane, Hsien-Yuan, additional, Kim, Yong Sik, additional, Kim, Se Hyun, additional, Rajkumar, Anto P., additional, González-Esquivel, Dinora F., additional, Jung-Cook, Helgi, additional, Baptista, Trino, additional, Rohde, Christopher, additional, Nielsen, Jimmi, additional, Verdoux, Hélène, additional, Quiles, Clelia, additional, Sanz, Emilio J., additional, De Las Cuevas, Carlos, additional, Cohen, Dan, additional, Schulte, Peter F.J., additional, Ertuğrul, Aygün, additional, Anıl Yağcıoğlu, A. Elif, additional, Chopra, Nitin, additional, McCollum, Betsy, additional, Shelton, Charles, additional, Cotes, Robert O., additional, Kaithi, Arun R., additional, Kane, John M., additional, Farooq, Saeed, additional, Ng, Chee H., additional, Bilbily, John, additional, Hiemke, Christoph, additional, López-Jaramillo, Carlos, additional, McGrane, Ian, additional, Lana, Fernando, additional, Eap, Chin B., additional, Arrojo-Romero, Manuel, additional, Rădulescu, Flavian Ş., additional, Seifritz, Erich, additional, Every-Palmer, Susanna, additional, Bousman, Chad A., additional, Bebawi, Emmanuel, additional, Bhattacharya, Rahul, additional, Kelly, Deanna L., additional, Otsuka, Yuji, additional, Lazary, Judit, additional, Torres, Rafael, additional, Yecora, Agustin, additional, Motuca, Mariano, additional, Chan, Sherry K.W., additional, Zolezzi, Monica, additional, Ouanes, Sami, additional, De Berardis, Domenico, additional, Grover, Sandeep, additional, Procyshyn, Ric M., additional, Adebayo, Richard A., additional, Kirilochev, Oleg O., additional, Soloviev, Andrey, additional, Fountoulakis, Konstantinos N., additional, Wilkowska, Alina, additional, Cubała, Wiesław J., additional, Ayub, Muhammad, additional, Silva, Alzira, additional, Bonelli, Raphael M., additional, Villagrán-Moreno, José M., additional, Crespo-Facorro, Benedicto, additional, Temmingh, Henk, additional, Decloedt, Eric, additional, Pedro, Maria R., additional, Takeuchi, Hiroyoshi, additional, Tsukahara, Masaru, additional, Gründer, Gerhard, additional, Sagud, Marina, additional, Celofiga, Andreja, additional, Ignjatovic Ristic, Dragana, additional, Ortiz, Bruno B., additional, Elkis, Helio, additional, Pacheco Palha, António J., additional, LLerena, Adrián, additional, Fernandez-Egea, Emilio, additional, Siskind, Dan, additional, Weizman, Abraham, additional, Masmoudi, Rim, additional, Mohd Saffian, Shamin, additional, Leung, Jonathan G., additional, Buckley, Peter F., additional, Marder, Stephen R., additional, Citrome, Leslie, additional, Freudenreich, Oliver, additional, Correll, Christoph U., additional, and Müller, Daniel J., additional
- Published
- 2021
- Full Text
- View/download PDF
17. Hacia la Receta Digital Nacional - Congreso Qu��mico Farmac��utico 2021
- Author
-
Olmos, Ismael
- Published
- 2021
- Full Text
- View/download PDF
18. European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed
- Author
-
Schoretsanitis, Georgios, primary, Smith, Robert L., additional, Molden, Espen, additional, Solismaa, Anssi, additional, Seppälä, Niko, additional, Kopeček, Miloslav, additional, Švancer, Patrik, additional, Olmos, Ismael, additional, Vázquez, Marta, additional, Iglesias-Garcia, Celso, additional, Iglesias-Alonso, Ana, additional, Spina, Edoardo, additional, and de Leon, Jose, additional
- Published
- 2021
- Full Text
- View/download PDF
19. Data sources for drug utilization research in Latin American (LatAm) countries
- Author
-
Lopes, Luciane Cruz, Salas, Maribel, Osorio-De-Castro, Claudia G. S., Acosta, Angela, Crisante, Maruja, Baldoni, Andre O., Dreser, Anahi, Castro-Pastrana, Lucila I., Sanchez-Salgado, Juan C., Tanta, Yesenia R., Mezones-Holguin, Edward, Delgado, Edgard N., Marin, Gustavo H., Canas, Martin, Tarapues, Monica, Duran, Carlos, Olmos, Ismael, Fonteles, Marta M. F., Silvio Barberato-Filho, Mota, Daniel M., Galicia, Diana L. G., Galvao, Tais F., Silva, Marcus T., Stichele, Robert V., Roldan, Juan, Wettermark, Bjorn, Bergamaschi, Cristiane C., Mena, Maria B., Medero, Natalia, Lima, Elisangela C., Marengo, Livia L., Lira, Ocelli I. H., Ali, Sanni, Santa-Ana-Tellez, Yared, Comoglio, Raquel H., Luiza, Vera L., Fulone, Izabela, Mazzei, Lauren G., Belen Mena, Maria, and Elsevier, Monique
- Published
- 2019
20. Evaluación y seguimiento del tratamiento con psicofármacos
- Author
-
Olmos, Ismael, Vázquez, .Marta, and Giachetto, Gustavo
- Subjects
PSICOFARMACOS ,MEDICAMENTOS ,SALUD MENTAL ,FARMACOLOGIA - Abstract
Esta tesis doctoral fue desarrollada desde la Unidad de Farmacología Clínica (perteneciente al Departamento de Farmacia del Hospital Vilardebó) y el Departamento de Ciencias Farmacéuticas de la Facultad de Química. En la misma se desarrollaron una serie de estudios de investigación con el objetivo del seguimiento y evaluación de pacientes en tratamientocon psicofármacosdonde algunas variables puedan influenciar la respuesta al tratamiento. Muchas veces no es el medicamento en sí mismo el culpable de no lograr los objetivos de efectividad y seguridad sino cómo essu usoen el escenario clínico. Son varias las fuentes de variación que pueden alterar la respuesta a un determinado medicamento. Ellas pueden ser: la hora de administrar el medicamento, la actividad física, los alimentos, la edad, el sexo, también las de origen farmacológico (comedicaciones, procesos farmacodinámicos del medicamento en cuestión), de origen tecnológico (distintas marcas comerciales del mismo principio activo, cómo se libera el fármaco desde la forma farmacéutica) o la propia patología o estado clínico del paciente.Se realizaron Estudios de Utilización de Medicamentos para conocer el uso de benzodiazepinas y antipsicóticos y su comparación con parámetros nacionales e internacionales. Los resultados hallados demuestran un uso poco armónico con las recomendaciones nacionales e internacionales. Dada esta problemática, desde la Unidad de Farmacología Clínica del Hospital Vilardebó se realizaron (y realizan) algunas actividades para mejorar el uso de psicofármacos en esta población. Un aspecto importante de esta tesis fue intentar determinar cómopueden influir diferentesmarcas comerciales de medicamentos en la respuesta al tratamiento. Se realizaron experiencias de comparación de marcas comerciales in vitroy experiencias de intercambio de marcas comerciales en pacientes del Hospital. Los resultados demuestran que salvo una marca de flunitrazepam el resto de los medicamentos estudiados (clozapina y lamotrigina) tienen una condiciónsuficientede calidad biofarmacéutica para estar en el mercado. Se realizó una encuesta a los pacientes sobre el consumo de plantas medicinales, una práctica que es poco tenida en cuenta a la hora de la prescripción, los resultados demuestranqueel consumo de plantas medicinales es elevado, con potenciales interacciones, que se deberían tener en cuenta al momento de la prescripción. Se profundizó en esta tesis la investigación en el uso clozapina en pacientes uruguayos con esquizofrenia con el objetivo principal de evaluar, utilizando metodologías de modelado poblacional, la amplitud y la variabilidad de la exposición a la clozapina y su metabolito activo (norclozapina) en los parámetros farmacocinéticos con un enfoque en el tabaquismo, la edad, el sexo, el consumo de cafeína, la comedicación y las marcas comerciales disponibles. Con esta tesis doctoralse pudo integrar eltrabajo profesional del Químico Farmacéutico desde la Unidad de Farmacología Clínica con algunas de las líneas desarrolladas en el Departamento de Ciencias Farmacéuticas con el objetivo de optimizar los tratamientos farmacológicos en los usuarios del Hospital Vilardebó.
- Published
- 2019
21. Prescripci��n de medicamentos y Farmacovigilancia
- Author
-
Olmos, Ismael
- Published
- 2018
- Full Text
- View/download PDF
22. Presentación del protcolo de utilización de clozapina en el Hospital Vilardebó - ASSE
- Author
-
Olmos, Ismael
- Published
- 2018
- Full Text
- View/download PDF
23. Una hipótesis sobre la supuesta falta de efectividad del midazolam inyectable
- Author
-
Olmos, Ismael, Ibarra, Manuel, M. Vázquez, and Fagiolino, Pietro
- Published
- 2018
- Full Text
- View/download PDF
24. Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia
- Author
-
Olmos, Ismael, primary, Ibarra, Manuel, additional, Vázquez, Marta, additional, Maldonado, Cecilia, additional, Fagiolino, Pietro, additional, and Giachetto, Gustavo, additional
- Published
- 2019
- Full Text
- View/download PDF
25. Population pharmacokinetics of clozapine and norclozapine in patientes with schizophrenia
- Author
-
Olmos, Ismael, Ibarra, Manuel, and Vázquez, Marta
- Published
- 2017
- Full Text
- View/download PDF
26. Consumo de benzodiazepinas en la población uruguaya: un posible problema de salud pública
- Author
-
Speranza, Noelia, Domínguez, Viviana, Pagano, Emiliano, Artagaveytia, Pía, Olmos, Ismael, Toledo, Mauricio, Tamosiunas, Gustavo, Speranza Noelia, Universidad de la República (Uruguay). Facultad de Medicina, Pagano Emiliano, Universidad de la República (Uruguay). Facultad de Medicina, Artagaveytia Pía, Universidad de la República (Uruguay). Facultad de Medicina, Olmos Ismael, Universidad de la República (Uruguay). Facultad de Medicina, Toledo Mauricio, Universidad de la República (Uruguay). Facultad de Medicina, Tamosiunas Gustavo, Universidad de la República (Uruguay). Facultad de Medicina, and Domínguez Viviana, Universidad de la República (Uruguay). Facultad de Medicina
- Subjects
BENZODIAZEPINAS ,BENZODIAZEPINES ,DRUG USE ,USO DE MEDICAMENTOS - Abstract
Resumen Objetivo: conocer el consumo de benzodiazepinas en Uruguay entre 2010 y 2012. Material y método: se realizó un estudio de utilización de medicamentos para evaluar el consumo de benzodiazepinas usando la dispensación de las farmacias de las instituciones participantes. Se utilizó la variable dosis diaria definida (DDD) por 1.000 habitantes/día (DHD). Se compararon las DHD anuales según el perfil hipnótico o ansiolítico y el subsector de asistencia, público o privado. Resultados: se incluyó el 62% de la población uruguaya. Las DHD globales de benzodiazepinas para los años 2010, 2011 y 2012 fueron 74,97, 75,17 y 71,14 DDD/1.000 personas/día, respectivamente (promedio 73,76). La benzodiazepina ansiolítica más consumida en el período analizado fue alprazolam (promedio 25,09). La benzodiazepina hipnótica más consumida fue flunitrazepam (promedio 18,69). Incluyendo clonazepam, esta fue la benzodiazepina más consumida (promedio 36,51) y los valores de consumo global aumentan a 106,36, 110,86 y 113,61 DDD/1.000 personas/día, respectivamente (promedio 110,28). Clonazepam fue la que presentó mayor incremento (35,29%), mientras que midazolam (-46,15%) y diazepam (-18,83%) fueron las que descendieron en mayor medida. El subsector público contribuyó principalmente al consumo global y el privado fue el que mayor aumento porcentual tuvo. Conclusión: Uruguay presenta un elevado consumo de benzodiazepinas, similar al hallado en otros países, pudiendo constituir un problema de salud pública. Este dato constituye el primero disponible en nuestro país y será útil para realizar futuras comparaciones. Es necesario implementar estrategias a nivel nacional que favorezcan un uso racional de benzodiazepinas. Abstract Objective: To quantify and evaluate benzodiazepines consumption in Uruguay between 2010 and 2012. Method: A study of utilization of drugs was conducted to assess benzodiazepines consumption in our population. Drug utilization data refers to oral benzodiazepines dispensed by the pharmacy departments from the participating health institutions. The unit of measurement was the defined daily doses (DDD) per 1000 inhabitants per day (DHD). DHD of hypnotic and anxiolytic benzodiazepines and DHD from public and private health care institutions were compared. Results were described as absolute values and percentage of changes. Results: Sixty two percent of the Uruguayan population was included in the study. Global DHD for 2010, 2011 and 2012 were 74.97, 75.17 and 71.14 (mean 73.76) DDD/1000 inhabitants/day respectively. Alprazolam was the most widely consumed anxiolytic benzodiazepine (mean 25.09) and flunitrazepam was the most commonly consumed hypnotic benzodiazepine (mean 18.69). If clonazepam is included, it becomes the most commonly consumed benzodiazepine (mean 36.51) and global DHD increases up to 106.36, 110.86 and 113.61 (mean 110.28) DDD/1000 inhabitants/day respectively. Clonazepam showed the higher consumption increase from 2010 to 2012 (35.29%), while the use of midazolam (-46.15%) and diazepam (-18.83%) gradually decreased. Public health institutions were responsible for most of the general consumption, whereas private institutions showed the higher increase in benzodiazepines consumption during the evaluated period. Conclusions: Uruguay showed high benzodiazepines consumption, similar to that reported by other countries and it seems to be an issue of public health concern. These are the first available benzodiazepines consumption data in our country and will be useful to perform future comparisons. Resumo Objetivo: conhecer o consumo de benzodiazepinas no Uruguai no período 2010-2012. Material e método: foi realizado um estudo sobre a utilização de medicamentos para avaliar o consumo de benzodiazepinas usando a dispensação nas farmácias das instituições participantes. A variável dose diária definida (DDD) por 1.000 habitantes/dia (DHD) foi utilizada. As DHD anuais foram comparadas segundo o perfil, hipnótico ou ansiolítico, e subsector de assistência, público ou privado. Resultados: 62% da população uruguaia foi incluída. As DHD globais de benzodiazepinas para os anos 2010, 2011 e 2012 foram 74,97, 75,17 e 71,14 DDD/1.000 pessoas/dia, respectivamente (média 73,76). A benzodiazepina ansiolítica mais consumida no período analisado foi alprazolam (média 25,09) e a hipnótica com maior consumo foi flunitrazepam (média 18,69). Incluindo clonazepam, esta foi a benzodiazepina mais consumida (média 36,51) e os valores de consumo global aumentam a 106,36, 110,86 e 113,61 DDD/1.000 pessoas/dia, respectivamente (média 110,28). O clonazepam foi a que apresentou o maior incremento (35,29%), sendo que o midazolam (-46,15%) e o diazepam (-18,83%) as que apresentaram uma maior redução de consumo. O subsector público contribuiu principalmente ao consumo global e o privado o que apresentou o maior aumento porcentual. Conclusão: o Uruguai apresenta um consumo elevado de benzodiazepinas, similar ao descrito em outros países, podendo ser um problema de saúde pública. Estes dados são os primeiros disponíveis no nosso país e serão úteis para futuras comparações. É necessário implementar estratégias a nível nacional que favoreçam um uso racional de benzodiazepinas.
- Published
- 2015
27. Uso de metilfenidato en niños y adolescentes usuarios de servicios de asistencia pública de Montevideo
- Author
-
Speranza, Noelia, Goyeneche, Noelia, Ferreiro, Daniela, Olmos, Ismael, Bauger, Mariana, Oyarzun, Mireille, Aramendi, Ines, Greckzanic, Ana, Giachetto, Gustavo, Speranza Noelia, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Goyeneche Noelia, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Ferreiro Daniela, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Olmos Ismael, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Bauger Mariana, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Oyarzun Mireille, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Aramendi Ines, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Greckzanic Ana, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, and Giachetto Gustavo, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica
- Subjects
Trastorno por trastorno por déficit de atención con hiperactividad ,Metilfenidato - Abstract
Introducción: el metilfenidato es el psicofármaco recomendado para el tratamiento del trastorno por déficit atencional e hiperactividad (TDAH), la alteración del comportamiento más frecuente en niños. En las farmacias del Centro Hospitalario Pereira Rossell (CHPR) y del Hospital Vilardebó (HV), responsables de la dispensación de metilfenidato a los beneficiarios de los servicios dependientes de la Administración de Servicios de Salud del Estado (ASSE), ésta se duplicó entre 2001 y 2006. A nivel internacional, recientemente se ha advertido sobre la aparición de reacciones adversas graves. Objetivo: describir el uso de metilfenidato en una población de niños beneficiarios del sector público de salud de Montevideo. Metodología: se identificaron los niños de 6 a 14 años que retiraron metilfenidato de las farmacias del CHPR y del HV, entre setiembre y diciembre de 2006. En base al número de niños potenciales usuarios de ASSE de Montevideo y la frecuencia estimada de la enfermedad (5%) se determinó el tamaño muestral en 114 (IC95%; imprecisión 3%). Se realizó una encuesta telefónica a los padres y/o tutores del niño en la que se analizó: indicación; prescripción; reacciones adversas; beneficio terapéutico. La calidad de la prescripción se evaluó mediante las Recomendaciones de la Academia Americana de Pediatría del año 2001. Resultados: se realizaron 124 encuestas. La edad media de los niños fue 10 años; 77% varones. El 93,5% (n=116) cumplía con los criterios diagnósticos de TDAH del DSM IV. La dosis media utilizada fue 12,9 mg. El 64,5% de los niños recibía el medicamento una vez al día, 27,4% dos veces/día, 5,6% tres veces/día y uno cuatro veces/día. El 85,5% recibía el medicamento antes de ir a la escuela. El 84,6% de los padres notaron beneficio terapéutico; el 56% de éstos recibía otro psicofármaco. En el 59,7% se comunicó una o más posibles reacciones adversas. Las más frecuentes fueron cefalea (29%), disminución del apetito (25%), dolor abdominal (24,2%). Discusión: no se identificaron problemas relacionados con la indicación, a pesar de las limitaciones de la aplicación de encuestas para su evaluación. El rango de dosis utilizadas coincide con las recomendadas. Llama la atención que la mayoría de los pacientes alcancen beneficio terapéutico con dosis bajas en una toma diaria. Este hallazgo podría explicarse por la relación de la administración con el horario escolar o con el uso combinado con otros psicofármacos. Las posibles reacciones adversas detectadas vinculadas a la administración de metilfenidato fueron un problema frecuente. La educación de los prescriptores y los usuarios resulta imprescindible para lograr un uso y monitorización adecuados de metilfenidato.
- Published
- 2008
28. Impacto de la protocolización de la profilaxis antibiótica en la cesárea en el centro Hospitalario Pereira Rossell
- Author
-
Kegel, Silvia, Speranza, Noelia, Telechea, Héctor, Olmos, Ismael, Greczanik, Ana, Giachetto, Gustavo, Nanni, Luciana, Kegel Silvia, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Speranza Noelia, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Telechea Héctor, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Olmos Ismael, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Greczanik Ana, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Giachetto Gustavo, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, and Nanni Luciana, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica
- Subjects
lcsh:R5-920 ,PROFILAXIS ANTIBIOTICA ,URUGUAY ,lcsh:R ,CESAREA ,Uruguay ,lcsh:Medicine ,Cesárea ,lcsh:Medicine (General) ,Profilaxis antibiótica - Abstract
Introducción: en julio de 2002, en el Centro Hospitalario Pereira Rossell (CHPR) se implementó una pauta de profilaxis antibiótica en la cesárea que consiste en la administración de cefazolina 2g intravenosa posclampeo del cordón umbilical. Objetivo: evaluar el cumplimiento de la pauta de profilaxis antibiótica en la cesárea en el CHPR y su impacto sobre el consumo y gasto de antibióticos. Material y método: se comparó el cumplimiento de la pauta a través del análisis del perfil farmacológico individual (antibiótico indicado; vía, momento y duración de la administración) en noviembre de 2002 versus noviembre de 2004. Se comparó el impacto de la aplicación de la pauta a través de la evolución mensual del consumo (DDD/100 camas día) (dosis diarias definidas/días camas ocupadas) y gasto en antibióticos (U$S) en el período mayo-noviembre de 2002 versus mayo-noviembre de 2004. Los datos fueron obtenidos a través del sistema de distribución y dispensación de medicamentos por dosis unitaria y de las historias clínicas. Resultados: la pauta se cumplió en 85% (n=41) de las pacientes analizadas en 2002 y en 65% (n=47) de las analizadas en 2004 (p
- Published
- 2007
29. Uso racional de medicamentos: ¿qué conocen los médicos residentes sobre los fármacos de uso corriente?
- Author
-
Giachetto, Gustavo, Banchero, Patricia, Telechea, Héctor, Speranza, Noelia, Wolaj, Mijal, Toledo, Mauricio, Olmos, Ismael, Camacho, Gabriela, Kegel, Silvia, Nanni, Luciana, Seade, Carolina, Giachetto Gustavo, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Banchero Patricia, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Telechea Héctor, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Speranza Noelia, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Wolaj Mijal, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Toledo Mauricio, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Olmos Ismael, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Camacho Gabriela, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Kegel Silvia, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, Nanni Luciana, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica, and Seade Carolina, Universidad de la República (Uruguay). Departamento de Farmacología y Terapéutica
- Subjects
DESCRIPCIÓN DE MEDICAMENTOS ,UTILIZACIÓN DE medicamentos - Abstract
Introducción: El uso irracional de los medicamentos constituye un riesgo inadmisible para los pacientes y un continuo derroche de recursos. De los diversos factores que contribuyen a esta realidad, el hábito de prescripción de los médicos es uno de los más frecuentes. La prescripción es un proceso razonado que exige el uso de información actualizada e independiente sobre los medicamentos. Objetivo: Conocer la información que tienen los médicos residentes de pediatría y medicina interna sobre medicamentos de uso frecuente. Material y método: En diciembre de 2002 se encuestaron en forma personal y anónima, 69 médicos residentes (38 de pediatría y 31 de medicina interna). Se evaluó el conocimiento sobre nombre genérico, dosis, efectos adversos y contraindicaciones absolutas de medicamentos de uso frecuente en cada una de las disciplinas. Las respuestas fueron catalogadas como verdaderas o falsas utilizando un estándar elaborado por los autores. Resultados: Los porcentajes de respuestas verdaderas entre los residentes de pediatría fueron: genérico 82%, dosis 42%, efectos adversos comunes 16%, efectos adversos graves 16% y contraindicaciones 32%. Entre los residentes de medicina interna: genérico 89%, dosis 53%, efectos adversos comunes 16%, efectos adversos graves 45% y contraindicaciones 46%. Se observó una proporción mayor de respuestas verdaderas estadísticamente significativa, entre los residentes de medicina interna en relación a las dosis, efectos adversos graves y contraindicaciones. Conclusiones: Una elevada proporción de los residentes encuestados no tiene conocimientos suficientes en relación a las dosis, los efectos adversos y las contraindicaciones de estos medicamentos de uso frecuente. Esto constituye un factor determinante en la prescripción irracional de los medicamentos. Es necesario fortalecer la formación continua en farmacología y terapéutica de los médicos residentes para revertir este problema. Summary Background. Non rational use of medicines is a needless risk for patients and a lost of sources. Prescription habits of surgeons are one of the causes of non-rational use of medicines. Prescription is a process that requires updated and independent information about medicines. Objective. To determine knowledge about common medicines in pediatricians and internal medicine residents. Method. In December 2002 a personal and anonymous questionnaire was answered by 69 residents (38 pediatricians and 31 internal medicine). Information on generic name, dosage, adverse reactions and contraindications of medicines of common use was inquired for each group of specialists. Answers were classified as true or false according to a standard designed by the authors. Results. Pediatric residents gave the following true answers: generic name 82%, dosage 42%, common adverse reactions 16%, serious adverse reactions 16%, and contraindications 32%. Among internal medicine residents, true answers were: Generic name 89%, dosage 53%, common adverse reactions 16%, serious adverse reactions 45%, and contra-indications 46%. Proportion of true responses was higher in internal medicine residents in relation to dosage, serious adverse reactions. Résumé Introduction: L'emploi irrationnel des médicaments constitue un risque inadmissible pour les patients et un continuel gaspillage des ressources. Parmi les facteurs responsables, la prescription médicale en est un des plus fréquents. But: Connaître l'information que les médecins pédiatres et les internes ont sur ces médicaments. Matériel et méthodes: En décembre 2002, on a enquêté sous forme anonyme et personnelle 69 médecins résidents (dont 38 de pédiatrie et 31 de médecine interne). On évalue les connaissances sur le nom générique, la dose, les effets adverses et contre-indications des médicaments à emploi fréquent dans chaque discipline. Les réponses ont été classées comme vraies ou fausses, selon le barème établi par les auteurs. Résultats: Les pourcentages de réponses vraies parmi les résidents de Pédiatrie ont été: générique 82%, dose 42%, effets adverses communs 16%, effets adverses graves 16% et contre-indications 32%. Parmi les résidents de Médecine Interne: générique 89%, dose 53%, effets adverses communs 16%, graves 45% et contre-indications 46%. On observe une différence significative au pourcen-tage de réponses vraies parmi les résidents de Médecine Interne. Conclusions: Un grand nombre des résidents enquêtés n'ont pas de connaisances suffisantes en ce qui concerne les doses, les effets adverses et les contre-indications des médicaments à emploi fréquent. Cela constitue un facteur déterminant de la prescription médicale irrationnelle des médicaments. Il faut insister sur la formation continue en Pharmacologie et en Thérapeutique des médecins résidents pour solutionner ce problème.
- Published
- 2003
30. Las políticas públicas aplicadas espacio público Bogotá 2010 - 2014
- Author
-
Castillo Olmos, Ismael Hernando, Jiménez Garzón, Zulman Janneth, and Domínguez García, Clara Inés
- Subjects
Espacio público accesible y de calidad ,Espacio público ,BOGOTA (COLOMBIA) - ADMINISTRACION PUBLICA ,ESPACIOS ABIERTOS - BOGOTA (COLOMBIA) ,Espacio público efectivo ,Bienes de uso público ,Espacio público sostenible - Abstract
El presente ensayo pretende, analizar si las políticas de espacio público con relación a los vendedores informales y la recuperación del mismo de igual forma verificar si estas políticas cumplen con los preceptos del Estado Social de Derecho, para esto se describieron los elementos más importantes de la Política de Espacio Público, los recursos, su financiación e impacto.
- Published
- 2013
31. Consultas por sangrados relacionados con medicamentos en el Servicio de Emergencia de la Asociación Española Primera de Socorros Mutuos
- Author
-
Olmos, Ismael, Daners, Martín, Olmos, Virginia, and Giachetto, Gustavo
- Subjects
HEMORRHAGE ,PHARMACEUTICAL PREPARATIONS ,PREPARACIONES FARMACÉUTICAS ,HEMORRAGIA - Abstract
Introducción: en el año 2007, las reacciones adversas a medicamentos (RAM) determinaron 4,1% de las hospitalizaciones en la Asociación Española Primera de Socorros Mutuos (AEPSM). La hemorragia digestiva asociada con anticoagulantes y antiinflamatorios no esteroideos (AINE) representó un problema frecuente. Objetivos: determinar la frecuencia y las características de los pacientes que consultan por sangrados o alteraciones de la crasis vinculadas a medicamentos, o ambas, en el servicio de emergencia de la AEPSM. Material y método: se analizaron todas las consultas realizadas en el servicio de emergencia por sangrados o alteraciones de la crasis, o ambas, entre el 24 de marzo y el 23 de abril de 2008. Se incluyeron aquellas que cumplieron con el criterio de diagnóstico de sangrado o alteración del INR por medicamentos Se analizaron las siguientes variables: edad, sexo, medicamentos implicados, tipo de sangrado y gravedad. Resultados: consultaron por este tipo de RAM 30 pacientes (0,45%; IC95% 0,42-0,47), de los cuales 20 fueron hospitalizados (1,27%; IC95% 1,30-1,24). Las RAM estuvieron relacionadas con anticoagulantes (n=19) y AINE (n=11). En el grupo de RAM por anticoagulantes la edad promedio fue 77 años, el fármaco más frecuente fue warfarina, 15 pacientes presentaron cinco o más medicamentos concomitantes (polifarmacia) y un paciente falleció. En el grupo de RAM por AINE la edad promedio fue de 69 años, el fármaco más frecuente fue el ácido acetilsalicílico, ocho pacientes tenían polifarmacia y cuatro pacientes estaban automedicados. Conclusiones: los sangrados vinculados a medicamentos constituyen un problema de salud grave. La mayoría de éstos ocurre en pacientes con factores de riesgo para el desarrollo de enfermedad producida por medicamentos. Es necesario planificar estrategias para disminuir el impacto de este problema Summary Introduction: during 2007, adverse drug reaction (ADR) determined 4.1% of hospitalizations at Asociación Española Primera de Socorros Mutuos (AEPSM). Gastrointestinal bleeding associated to non-steroidal anticoagulants (NSAID) was a frequent problem. Objectives: to determine frequency and characteristics of patients who consult for bleeding or alterations in blood crasis associated to drugs, or both, at the Emergency Unit of the AEPSM. Method: the study analysed all consultations due to bleeding or crasis alterations, or both, at the emergency service between March 24 and April 23, 2008. Those complying with the diagnostic criteria of bleeding or INR alterations were included. The following variables were analysed: age, sex, drugs implied, type of bleeding and severity. Results: 30 patients (0.45%; IC95% 0.42-0.47) consulted for adverse drug reaction, and 20% of them were hospitalized (1.27%; IC95% 1.30-1.24). ADR were related to anticoagulants (n=19) and non-steroidal anti-inflammatory drugs (n=11). In the ADR due to anticoagulants, average age was 77 and the most frequent drug was warfarina. 15 patients presented five or more concomitant drugs and one patient died. In the ADR group with non-steroidal anti-inflammatory drugs average age was 69, and the most frequent drug was acetylsalicylic acid, eight patients presented polypharmacy and four patients evidenced self-medication. Résumé Introduction: en 2007, les réactions adverses à des médicaments (RAM) ont déterminé 4,1% des hospitalisations à l'Asociación Española Primera de Socorros Mutuos (EAPSM). L'hémorragie digestive associée aux anticoagulants et aux anti-inflammatoires pas stéroïdiens (AINS) fut fréquente. Objectif : déterminer la fréquence et les caractéristiques des patients qui consultent pour des troubles de la crase ou pour hémorragies liées à des médicaments, ou les deux, au service d'urgences de l'EAPSM. Matériel et méthode: on a analysé toutes les consultations réalisées au service d'urgences pour hémorragies ou troubles de la crase, ou les deux, entre le 24 mars et le 23 avril 2008. Les consultations qui suivaient les critères de diagnostic d'hémorragie ou de trouble du INR par médicaments. On a tenu compte des variables d'âge, de sexe, des médicaments en question, du type d'hémorragie ou de la sévérité. Résultats: 30 patients (0,45%; IC95% 0,42-0,47%) ont consulté dont 10 ont été hospitalisés (1,27% IC95% 1,30-1,24). Les RAM ont été liées à des anticoagulants (n=19) y AINE (n=11). Dans le groupe de RAM par anticoagulant, l'âge moyen fut de 77 ans, le médicament le plus utilisé, warfarine, 15 patients ont présenté 5 ou plus de 5 médicaments concomitants (polypharmacie) et un patient a décédé. Dans le groupe de RAM par AINS l'âge moyen fut de 69 ans, le médicament le plus utilisé l'acide acétylsalicylique, huit patients subissaient polypharmacie et quatre s'automédicaient. Conclusions: les hémorragies liées à des médicaments constituent un grave problème de santé. La plupart atteint des patients ayant des facteurs de risque pour le développement des maladies provoquées par les médicaments. Il s'avère nécessaire de planifier des stratégies pour diminuer l'impact de ce problème. Resumo Introdução: 4,1% das internações feitas durante 2007 na Asociación Española Primera de Socorros Mutuos (AEPSM) foram causadas por reações adversas a medicamentos (RAM). A hemorragia digestiva associada a anticoagulantes e antiinflamatórios não esteróides (AINE) foi um problema freqüente. Objetivos: determinar a freqüência e as características dos pacientes que consultaram por sangramentos ou alterações da crase associadas a medicamentos ou ambas, no Pronto-Socorro da AEPSM. Material e método: Todas as consultas realizadas no Pronto-Socorro por sangramento ou alterações da crase ou ambas no período 24 de marco-23 de abril de 2008 foram analisadas. O critério de inclusão foi diagnóstico de sangramento ou alteração do INR por medicamentos. Foram analisadas as seguintes variáveis: idade, sexo, medicamentos implicados, tipo de sangramento e severidade. Resultados: trinta pacientes consultaram por esse tipo de RAM (0,45%; IC 95% 0,42-0,47) sendo que 20 foram hospitalizados (1,27%; IC95% 1,30-1,24). As RAM estavam vinculadas a anticoagulantes (n=19) e AINE (n=11). No grupo de RAM causadas por anticoagulantes a idade media foi 77 anos, o fármaco mais freqüente foi a warfarina, 15 pacientes tomavam cinco ou mais medicamentos concomitantemente (polifarmácia) e um paciente faleceu. No grupo de RAM por AINE a idade média foi 69 anos, o fármaco mais freqüente foi o ácido acetilsalicílico, oito pacientes apresentavam polifarmácia e quatro estavam automedicados. Conclusões: os sangramentos vinculados a medicamentos são um grave problema de saúde. A maioria ocorre em pacientes com fatores de risco para desenvolver patologias produzidas por medicamentos. É necessário planejar estratégias para diminuir o impacto deste problema.
- Published
- 2011
32. Hyperammonemia Associated with Valproic Acid Concentrations
- Author
-
Vázquez, Marta, primary, Fagiolino, Pietro, additional, Maldonado, Cecilia, additional, Olmos, Ismael, additional, Ibarra, Manuel, additional, Alvariza, Silvana, additional, Guevara, Natalia, additional, Magallanes, Laura, additional, and Olano, Ivette, additional
- Published
- 2014
- Full Text
- View/download PDF
33. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels.
- Author
-
de Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Seppälä N, Kopeček M, Švancer P, Olmos I, Ricciardi C, Iglesias-Garcia C, Iglesias-Alonso A, Spina E, Ruan CJ, Wang CY, Wang G, Tang YL, Lin SK, Lane HY, Kim YS, Kim SH, Rajkumar AP, González-Esquivel DF, Jung-Cook H, Baptista T, Rohde C, Nielsen J, Verdoux H, Quiles C, Sanz EJ, De Las Cuevas C, Cohen D, Schulte PFJ, Ertuğrul A, Anıl Yağcıoğlu AE, Chopra N, McCollum B, Shelton C, Cotes RO, Kaithi AR, Kane JM, Farooq S, Ng CH, Bilbily J, Hiemke C, López-Jaramillo C, McGrane I, Lana F, Eap CB, Arrojo-Romero M, Rădulescu FŞ, Seifritz E, Every-Palmer S, Bousman CA, Bebawi E, Bhattacharya R, Kelly DL, Otsuka Y, Lazary J, Torres R, Yecora A, Motuca M, Chan SKW, Zolezzi M, Ouanes S, De Berardis D, Grover S, Procyshyn RM, Adebayo RA, Kirilochev OO, Soloviev A, Fountoulakis KN, Wilkowska A, Cubała WJ, Ayub M, Silva A, Bonelli RM, Villagrán-Moreno JM, Crespo-Facorro B, Temmingh H, Decloedt E, Pedro MR, Takeuchi H, Tsukahara M, Gründer G, Sagud M, Celofiga A, Ignjatovic Ristic D, Ortiz BB, Elkis H, Pacheco Palha AJ, LLerena A, Fernandez-Egea E, Siskind D, Weizman A, Masmoudi R, Mohd Saffian S, Leung JG, Buckley PF, Marder SR, Citrome L, Freudenreich O, Correll CU, and Müller DJ
- Subjects
- Adult, Asian People, C-Reactive Protein, Female, Humans, Male, Valproic Acid adverse effects, Antipsychotic Agents adverse effects, Clozapine adverse effects
- Abstract
This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas' original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300-600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75-150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175-300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100-200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250-400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150-300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300-600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration., Competing Interests: In the last 3 years, the following authors had no conflict of interest: Drs. de Leon, Schoretsanitis, Molden, Smith, Solismaa, Švancer, Olmos, Ricciardi, Iglesias-Garcia, Iglesias-Alonso, Spina, Ruan, Chuan-Yue Wang, Gang Wang, Tang, Lin, Lane, Rajkumar, González-Esquivel, Jung-Cook, Baptista, Rohde, Nielsen, Verdoux, Quiles, Sanz, De las Cuevas, Cohen, Schulte, Chopra, McCollum, Shelton, Kaithi, Farooq, McGrane, Lana, Arrojo-Romero, Rădulescu, Every-Palmer, Bebawi, Bhattacharya, Otsuka, Lazary, Torres, Yecora, Motuca, Chan, Zolezzi, Ouanes, De Berardis, Grover, Kirilochev, Soloviev, Ayub, Silva, Bonelli, Temmingh, Decloedt, Pedro, Pacheco Palha, LLerena, Fernandez-Egea, Siskind, Masmoudi, Mohd Saffian, Leung and Buckley. In the last 3 years several authors report conflicts of interests. Dr. Seppälä is permanent medical advisor, received lecture fees and is an advisory board member from Viatris that markets clozapine in Finland and other European countries. Dr. Kopeček participated in speakers/advisory boards and lectured with the support of Angelini, Janssen Pharmaceuticals, Lundbeck and Richter Gedeon. Dr. Yong Sik Kim received grants, research support and honoraria from Janssen, Otsuka, Whan in Pharm and Bukwang Pharm (Sumitomo Dannipon Pharma). Dr. Se Hyun Kim received research grants from and/or served as a lecturer for Janssen, Eli Lilly, and Dongwha. Dr. Ertuğrul has received speaker’s honoraria from Abdi İbrahim Otsuka. Dr. Anıl Yağcıoğlu has received speaker’s honoraria and consulting fees from Janssen and Abdi İbrahim Otsuka. Dr. Cotes has received research funding from Otsuka, Lundbeck, Roche, Alkermes, and is a consultant for Saladax Biomedical. Dr. Kane reports personal fees from Alkermes, personal fees from Allergan, personal fees from Bristol-Myers Squibb, personal fees from IntraCellular Therapies, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Sunovion, Takeda, Teva, outside-the-submitted work from LB Pharma, MedAvante and The Vanguard Research Group. Dr. Ng had served as consultant for Grunbiotics, Lundbeck, Servier, and Janssen-Cilag, and received research speaker honoraria from Servier, Janssen-Cilag and Pfizer.IMcG received royalties from Hogrefe Publishing Corp. T.L. Dr. Bilbily is supported by the National Institute on Drug Abuse training grant 5T32DA007261-30 (MPI). Dr. Hiemke received speaker’s honoraria from Otsuka. Dr. López-Jaramillo reports financial support for research from Financial support from the National Institute of Mental Health, USA, MinCiencias, Colombia and the Universidad de Antioquia, Colombia. Dr. Eap received honoraria for conferences or teaching CME courses from Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Vifor-Pharma, and Zeller. Dr. Seifritz has received honoraria from Schwabe GmbH for educational lectures. He has further received educational grants and consulting fees from Janssen Cilag, Lundbeck, Angelini, Otsuka, Servier, Recordati, Vifor, Sunovion, and Mepha. Dr. Bousman is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Pharmacogene Variation Consortium (PharmVar). Dr. Kelly has served as a consultant for Alkermes, Lyndra and Sunovion. Dr. Procyshyn has been on the speaker's bureau and attended advisory board meetings for Janssen, Lundbeck, and Otsuka. Dr. Adebayo was on the advisory board of Janssen for a Long Acting Injectable Paliperidone palmitate in Nigeria. Janssen is not involved in Clozapine in Nigeria. Dr. Fountoulakis has received grants in the past, served as consultant, advisor or CME speaker, or received support to attend congresses by the following entities: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Pfizer, the Pfizer Foundation, Sanofi-Aventis, Servier, Shire and others. Since January 2020 he has been the director of Cochrane Greece and completely free from any conflict of interest. Dr. Wilkowska has received research support from Angelini, Biogen, Eli Lilly and Company, Janssen-Cilag, Lundbeck, Polpharma, Sanofi and Valeant. Dr. Cubała has received research support from Alkermes, Allergan, Auspex, Biogen, Celon, Ferrier, Forest Laboratories, Janssen, Otsuka, and Sanofi; he has served on speaker bureaus for Angelini, Celon, Janssen, and Sanofi, and he has served as a consultant for GW Pharmaceuticals, Janssen, Celon and Sanofi. Dr. Villagrán-Moreno has received speakerʼs honoraria from Janssen and have developed lectures and presented clozapine lectures for Adamed, which sells clozapine in Spain; he has participated in advisory boards for Rovi and in research projects for Otsuka. Dr. Crespo-Facorro has received funding unrelated to the present work for research projects and/or honoraria as a consultant or speaker from the following entities: Angelini, Janssen-Cilag, Lundbeck, Otsuka, Mylan, Sanofi-Aventis, ADAMED, Agencia Española de Investigacion, Instituto de Salud Carlos III, the EU Seventh Framework Program and Horizon 2020. Dr. Takeuchi has received speaker’s fees from EA Pharma, Kyowa, Janssen, Lundbeck, Meiji Seika Pharma, Mochida, Otsuka, Sumitomo Dainippon Pharma, Takeda, and Yoshitomiyakuhin. Dr. Tsukahara has received speaker's honoraria from Eisai Inc. Dr. Gründer has served as a consultant for Allergan (Dublin, Ireland), Boehringer Ingelheim (Ingelheim, Germany), Institute for Quality and Efficiency in Health Care (IQWiG, Cologne, Germany), Janssen-Cilag (Neuss, Germany), Lundbeck (Copenhagen, Denmark), Otsuka (Chiyoda, Japan), Recordati (Milan, Italy), Sage (Cambridge, USA), and Takeda (Osaka, Japan). He has served on the speakers’ bureau of Gedeon Richter (Budapest, Hungary), Janssen Cilag, Lundbeck, Otsuka, Recordati. He has received grant support from Boehringer Ingelheim, Lundbeck and Saladax (Bethlehem, USA). He is co-founder and/or shareholder of Mind and Brain Institute GmbH (Zornheim, Germany), Brainfoods GmbH (Zornheim, Germany), OVID Health Systems GmbH (Berlin, Germany) and MIND Foundation gGmbH (Berlin, Germany). Dr. Sagud participated in lectures for the following companies: Alkaloid, Belupo, Elli Lilly, Gedeon Richter, Jadran Galenski Laboratorij, Johnson / Johnson, Lundbeck, Makpharm, Pliva, Stada and participated in the clinical trial: Eli Lilly, Krka and Gedeon Richter. Dr. Celofiga received speaker’s honoraria from Ely Lilly, Lundbeck, Richter Gedeon, Krka, Lek, Pliva, Angelini Pharma and participated in advisory boards for Janssen Pharmaceuticals and Lundbeck. Dr. Ignjatovic Ristic developed and presented clozapine lectures with the support of Mylan, received speakerʼs honoraria from Mylan, Teva Serbia, Pharm Swiss, Krka and Janssen. Dr. Ortiz has been a consultant and has received honoraria from Janssen-Cilag. Dr. Elkis received research grants from the São Paulo Research Support Foundation (FAPESP) and honoraria for participation as a member of advisory boards, speaker, or travel support from the following pharmaceutical companies: Aché, Cristalia, Daiichi-Sankyo, Janssen, Mantecorp-Hypera, Sandoz, and Teva. Dr. Weizman received speakerʼs honoraria from Lundbeck, Lilly, Teva, Trima, Jansen, Medison, Novartis and AstraZeneca. These activities were unrelated to the current study. Dr Marder reports consultation fees from Roche, Sunovion, Merck, Boehringer Ingelheim and Otsuka. He reports research support from Boehringer-Ingelheim, and GW Pharma. Dr. Citrome has engaged in collaborative research with, or received consulting or speaking fees, from: AbbVie, Acadia, Alexza, Alkermes, Allergan, Angelini, Astellas, AstraZeneca, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Bristol-Myers Squibb, Cadent Therapeutics, Eisai, Eli Lilly, Forum, Genentech, Impel, Indivior, Intra-Cellular Therapies, Janssen, Jazz, Karuna, Lundbeck, Luye, Lyndra, Medavante-Prophase, Meiji, Merck, Medivation, Mylan, Neurocrine, NeuroRx, Novartis, Noven, Osmotica, Otsuka, Pfizer, Reckitt Benckiser, Relmada, Reviva, Sage, Shire, Sunovion, Takeda, Teva, University of Arizona, Valeant, Vanda, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research. Dr. Freudenreich has the following financial relationship with a commercial interest to disclose (recipient SELF; content area SCHIZOPHRENIA): Alkermes – Research grant (to institution), consultant honoraria (Advisory Board); Avanir – Research grant (to institution); Janssen – Research grant (to institution), consultant honoraria (Advisory Board); Integral - Consultant honoraria; Neurocrine – Consultant honoraria (Advisory Board); Novartis – Consultant honoraria; Otsuka – Research grant (to institution); Roche – Consultant honoraria; Springer Verlag – Royalties (medical writer); Elsevier – Honoraria (medical editing); Global Medical Education – Honoraria (CME speaker and content developer); Medscape – Honoraria (CME speaker); American Psychiatric Association – Consultant honoraria (SMI Adviser); Wolters-Kluwer – Royalties (content developer); UpToDate – Royalties, honoraria (content developer and editor, including for a chapter on clozapine). Dr. Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Damitsa, Gedeon Richter, Hikma, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of LB Pharma. Dr. Müller reports he has been a co-investigator for two pharmacogenetic studies where genetic test kits were provided as an in-kind contribution by Myriad Neuroscience. He did not receive any payments or any equity, stocks, or options from any pharmacogenetic companies. He is also a co-inventor of two patents assessing risk for antipsychotic-induced weight gain (pending)., (Thieme. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.